mdi Consultants, Inc
07
Jul
Is Your Product Still an FDA-Regulated Device in 2026?
The Answer Might Surprise You. One of the most common questions we have received from manufacturers, software developers, and startup founders this year is: Is my product still considered a medical device by the FDA?" The short answer is: maybe not—but don't assume. In 2026, the FDA continued refining its approach to certain low-risk health
06
Jul
Avoiding FDA regulatory issues in your device development
Why Medical Device Startups Struggle With FDA Regulatory Approval: 10 Common Mistakes Quick Answer Medical device startups most often fail to reach market on time because they treat FDA regulatory compliance as a final step rather than building it into product design from the concept stage. The 10 most common causes of medical device startup
The Mid-Year FDA Compliance Check: 5 Things to Verify Before Q3
Short answer: Before Q3 begins, medical device companies should verify five key compliance areas: FDA establishment registration, QMSR implementation, inspection readiness, U.S. Agent designation (for foreign manufacturers), and the status of any open FDA 483 corrective actions. Addressing these items now can help avoid compliance issues and last-minute challenges during the October registration renewal period.
16
Jun
FDA Establishment Registration for Medical Devices — What Foreign Manufacturers Get Wrong
For foreign medical device firms, FDA establishment registration and U.S. Agent designation are not optional—they are mandatory requirements for accessing the U.S. market. Errors in either process can lead to shipment delays, import holds, or FDA Import Alerts that disrupt business operations and market access. Drawing on nearly 50 years of regulatory experience and
10
Jun
What FDA Inspectors Are Actually Checking Under the New QMSR — MDI’s First-Hand Findings
What FDA Inspectors Are Actually Checking Under the New QMSR — MDI’s First-Hand Findings The single biggest focus area in every QMSR inspection that MDI has participated in is not your quality manual, SOPs/work instruction, documentation structure or your terminology — it is your organizations ability to demonstrate risk-based thinking embedded throughout your entire quality
09
Jun
First New UV Filter Approved in Over 20 Years!
FDA Opens the Door to Sunscreen Innovation: First New UV Filter Approved in Over 20 Years! The U.S. Food and Drug Administration (FDA) has finalized an administrative order adding bemotrizinol to the Over-the-Counter (OTC) Sunscreen Monograph, making it the first new sunscreen active ingredient approved for inclusion in the U.S. OTC sunscreen framework in more
08
Jun
How to Respond to an FDA 483 and Warning Letter – Precautionary Measures
The FDA themselves state it is industry’s responsibility to work with investigators before they leave the company to remove all incorrect points on the 483. The FDA is also supposed to annotate the 483 concerning your corrective actions that were accomplished during the inspection. From latest experience with the new FDA investigators, this advice doesn’t
26
May
How to Respond to an FDA 483
FDA Inspections & Compliance How to Respond to an FDA 483 — and Prevent a Warning Letter A company that receives a Form 483 has one opportunity to demonstrate control, credibility, and corrective action before the FDA decides whether to escalate. This guide — written by a former FDA field investigator — shows exactly how
07
May
FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight
FDA Update PLEASE BE AWARE THAT THE FDA HAS LAUNCHED THE FOLLOWING PROGRAM. WHAT DOES IT MEAN TO YOU? FDA Launches One-Day Inspectional Assessments to Strengthen and Expand Oversight The U.S. Food and Drug Administration today announced that it is piloting one-day inspectional assessments, as part of a broader initiative to make its inspectional resources